-
A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)McMurray JJV, DeMets DL, DAPA-HF Committees and Investigators. -
Association of Cardiovascular Disease With Respiratory DiseaseP Carter, J Lagan, C Fortune et al.
-
Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection FractionSD Solomon, the PARAGON-HF Investigators and Committees. JohnJV McMurray,
-
SPECT and PET in ischemic heart failureAngelidis G, Giamouzis G, Karagiannis G et al.
-
Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionMcMurray JJV, SD Solomon, DAPA-HF Committees and Investigators.
-
Permanent pacemaker use among patients with heart failure and preserved ejection fraction: Findings from the Acute Decompensated Heart Failure National Registry (ADHERE) National RegistryKhazanie P, Hellkamp AS, Hernandez AF et al.
-
Modifiable lifestyle factors and heart failure: A Mendelian randomization studyS van Oort, JWJ Beulens, AJ van Ballegooijen et al.
-
Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart FailureMcMurray JJ, Krum H, ATMOSPHERE Committees Investigators.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
